argenx SE (ARGNF)
USD 697.42
(0.33%)
USD 697.42
(0.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.53 Billion USD | 38.89% |
| 2022 | 1.1 Billion USD | 30.14% |
| 2021 | 846.02 Million USD | 50.6% |
| 2020 | 561.76 Million EUR | 101.06% |
| 2019 | 279.4 Million EUR | 136.38% |
| 2018 | 118.2 Million EUR | 66.02% |
| 2017 | 71.19 Million EUR | 87.38% |
| 2016 | 37.99 Million EUR | 54.75% |
| 2015 | 24.55 Million EUR | 39.27% |
| 2014 | 17.63 Million EUR | 43.36% |
| 2013 | 12.29 Million EUR | -20.53% |
| 2012 | 15.47 Million EUR | 150.53% |
| 2011 | 6.17 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 936.29 Million USD | 108.32% |
| 2024 Q1 | 449.45 Million USD | 8.97% |
| 2023 Q1 | 304.28 Million USD | 10.6% |
| 2023 Q2 | 347 Million USD | 14.04% |
| 2023 FY | 1.52 Billion USD | 38.89% |
| 2023 Q4 | 412.47 Million USD | 10.39% |
| 2023 Q3 | 373.63 Million USD | 7.68% |
| 2022 Q4 | 275.12 Million USD | -18.2% |
| 2022 Q2 | 244.72 Million USD | -0.02% |
| 2022 Q1 | 244.76 Million USD | -8.7% |
| 2022 Q3 | 336.35 Million USD | 37.44% |
| 2022 FY | 1.1 Billion USD | 30.14% |
| 2021 FY | 846.02 Million USD | 50.6% |
| 2021 Q1 | 169.32 Million EUR | 123.6% |
| 2021 Q2 | 217.1 Million USD | 28.22% |
| 2021 Q3 | 213.81 Million USD | -1.52% |
| 2021 Q4 | 268.08 Million USD | 25.38% |
| 2020 Q4 | -717.39 Million USD | -1062.09% |
| 2020 Q3 | 74.56 Million EUR | 0.0% |
| 2020 FY | 561.76 Million EUR | 101.06% |
| 2019 FY | 279.4 Million EUR | 136.38% |
| 2019 Q1 | 47.72 Million EUR | 18.96% |
| 2019 Q2 | 63.7 Million EUR | 33.49% |
| 2019 Q3 | 57.62 Million EUR | -9.55% |
| 2019 Q4 | 93.81 Million EUR | 62.81% |
| 2018 Q4 | 40.11 Million EUR | 43.12% |
| 2018 Q2 | 25.75 Million EUR | 5.94% |
| 2018 Q1 | 24.3 Million EUR | 10.51% |
| 2018 FY | 118.2 Million EUR | 66.02% |
| 2018 Q3 | 28.02 Million EUR | 8.83% |
| 2017 Q1 | 16.08 Million EUR | 33.0% |
| 2017 FY | 71.19 Million EUR | 87.38% |
| 2017 Q4 | 21.99 Million EUR | 39.24% |
| 2017 Q3 | 15.79 Million EUR | -8.77% |
| 2017 Q2 | 17.31 Million EUR | 7.63% |
| 2016 Q4 | 12.09 Million EUR | 5.82% |
| 2016 FY | 37.99 Million EUR | 54.75% |
| 2016 Q3 | 11.43 Million EUR | 33.09% |
| 2016 Q2 | 8.58 Million EUR | 46.01% |
| 2016 Q1 | 5.88 Million EUR | -20.76% |
| 2015 FY | 24.55 Million EUR | 39.27% |
| 2015 Q4 | 7.42 Million EUR | 24.5% |
| 2015 Q3 | 5.96 Million EUR | -6.25% |
| 2015 Q2 | 6.35 Million EUR | 32.24% |
| 2015 Q1 | 4.8 Million EUR | -25.43% |
| 2014 FY | 17.63 Million EUR | 43.36% |
| 2014 Q4 | 6.44 Million EUR | 58.85% |
| 2014 Q2 | 4.04 Million EUR | 31.48% |
| 2014 Q1 | 3.07 Million EUR | 1.17% |
| 2014 Q3 | 4.05 Million EUR | 0.37% |
| 2013 Q3 | 1.77 Million EUR | -60.89% |
| 2013 Q2 | 4.53 Million EUR | 53.45% |
| 2013 Q4 | 3.04 Million EUR | 71.6% |
| 2013 FY | 12.29 Million EUR | -20.53% |
| 2013 Q1 | 2.95 Million EUR | 0.0% |
| 2012 FY | 15.47 Million EUR | 150.53% |
| 2011 FY | 6.17 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -114734.087% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -30314.848% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -5089.084% |
| Nascent Biotech, Inc. | 2.22 Million USD | -68671.893% |
| Rebus Holdings, Inc. | 664 Thousand USD | -230853.313% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -4016.232% |
| Qrons Inc. | 643.67 Thousand USD | -238145.269% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -393550.883% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -2569.795% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -368999.281% |
| Skye Bioscience, Inc. | 13.54 Million USD | -11219.611% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -1667.045% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -31082.536% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -585829.56% |
| SQZ Biotechnologies Company | 85.61 Million USD | -1691.109% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -52485.954% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -102006.067% |
| Mesoblast Limited | 5.9 Million USD | -25883.226% |
| Marizyme, Inc. | 19.23 Million USD | -7870.6% |
| Genus plc | 147.7 Million USD | -938.274% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -17367.697% |
| Pharming Group N.V. | 225.49 Million USD | -580.085% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -74753.627% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -114210.739% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -18289.855% |
| ContraFect Corporation | 56.88 Million USD | -2595.653% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -34684.398% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -103604.34% |
| IMV Inc. | 37.7 Million USD | -3966.725% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -54858.201% |
| MultiCell Technologies, Inc. | 567.42 USD | -270263549.501% |
| ONE Bio Corp. | 6.44 Million USD | -23698.195% |
| Accustem Sciences Inc. | 3.74 Million USD | -40833.222% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -1684.316% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -288178.11% |
| Q BioMed Inc. | 3.43 Million USD | -44523.101% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -6104.855% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -58264.116% |
| Biomind Labs Inc. | 994.18 Thousand USD | -154150.429% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -1443.871% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -87048.331% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -22727.13% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -82154.595% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 6134220.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -9478.434% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -83466.791% |
| GB Sciences, Inc. | 1.42 Million USD | -107856.373% |
| Alpha Cognition Inc. | 9.7 Million USD | -15700.464% |
| HST Global, Inc. | 140.9 Thousand USD | -1088227.762% |
| CSL Limited | 3.44 Billion USD | 55.537% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -136224.684% |
| Halberd Corporation | 74.84 Thousand USD | -2048923.276% |
| Enzolytics Inc. | 2.17 Million USD | -70261.325% |
| Agentix Corp. | 1.37 Million USD | -111693.205% |
| Resverlogix Corp. | 12.71 Million USD | -11963.641% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -41906.384% |
| MetaStat, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -146789.847% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -63665.991% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -96998.499% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -44937.87% |
| AVAX Technologies, Inc. | 7.31 Million USD | -20877.765% |
| Zenith Capital Corp. | 8.94 Million USD | -17047.825% |
| Genscript Biotech Corporation | 825.34 Million USD | -85.805% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -8802666.776% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -62357.516% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -894039.666% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -79733.683% |
| Kadimastem Ltd | 2.41 Million USD | -63528.993% |
| Helix BioMedix, Inc. | 1.97 Million USD | -77663.872% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -14011.806% |
| BioStem Technologies, Inc. | 22.97 Million USD | -6574.834% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -844889.944% |
| LadRx Corporation | 3.81 Million USD | -40131.219% |
| Cell Source, Inc. | 4.32 Million USD | -35354.505% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -165954.509% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -165954.509% |
| NovAccess Global Inc. | 2.46 Million USD | -62067.758% |
| Affymax, Inc. | 39.38 Million USD | -3793.592% |
| Itoco Inc. | 919.14 Thousand USD | -166743.462% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -36081.694% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -136944.683% |
| Mobile Lads Corp. | 554.54 Thousand USD | -276437.925% |
| CytoDyn Inc. | 18.05 Million USD | -8392.247% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -6092831.781% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -696712.039% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -107910.892% |
| SYBLEU INC | 160.87 Thousand USD | -953137.276% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -84330.607% |
| International Stem Cell Corporation | 5.27 Million USD | -28993.72% |
| Bioxytran, Inc. | 3.82 Million USD | -40043.22% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2913030.2% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -7538267.006% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -4128.561% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -94679.357% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -208306.776% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -49193.796% |
| Neutra Corp. | 243.82 Thousand USD | -628857.309% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -8684.614% |
| PureTech Health plc | 144.59 Million USD | -960.555% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -7384.326% |
| IXICO plc | 4.7 Million USD | -32479.775% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -17332.42% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -1202.383% |
| CSL Limited | 3.89 Billion USD | 60.608% |
| Cellectis S.A. | 97.32 Million USD | -1475.76% |